Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-701 in Healthy Western and Asian Subjects
NCT06895343Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FG-M701 in solid tumor, sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events at 47 weeks, Maximum Plasma Concentration at 47 weeks and 3 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
FG-M701
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06895343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895343.